Consensus Beam Therapeutics Inc.

Stocks

BEAM

US07373V1052

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:23:11 10/11/26 am AEDT			5-day change	1st Jan Change
26.96 ^USD	+2.06%		+5.18%	-1.84%

05/11	BofA Securities Adjusts Price Target on Beam Therapeutics to $41 From $43	MT
05/11	Beam Therapeutics Presents Updated Clinical Data from Beacon Phase 1/2 Trial of Risto-Cel in Sickle Cell Disease	CI

Evolution of the Average Target: Beam Therapeutics Inc.

Evolution of the Target Price: Beam Therapeutics Inc.

Changes in Analyst Recommendations: Beam Therapeutics Inc.

477886bd2c5acae4ef51740a809aba1.noMMUtnynTy1PyrkdeORTnE-m9TH0jG65R-Xi_Sw5Ec.r8FGFO699kjAcXCvR9vBDTBN06GklmLNh1ag6aeBribu3GEC75HzSJhYQQ~b7bb6e10b46f8c3621bf4edef32870d5

Analysts' recommendations: Beam Therapeutics Inc.

05/11	BofA Securities Adjusts Price Target on Beam Therapeutics to $41 From $43	MT
04/11	Wedbush Adjusts Price Target on Beam Therapeutics to $30 From $28, Keeps Outperform Rating	MT
28/10	Wedbush Adjusts Beam Therapeutics PT to $28 From $65, Maintains Outperform Rating	MT
05/08	BofA Adjusts Price Target on Beam Therapeutics to $43 From $47	MT
26/02	RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector Perform - Speculative Risk Rating	MT
25/02	Wedbush Raises Beam Therapeutics Price Target to $65 From $57, Maintains Outperform Rating	MT
20/02	Canaccord Genuity Initiates Beam Therapeutics at Buy With $74 Price Target	MT
08/01	UBS Initiates Beam Therapeutics at Neutral With $28 Price Target	MT
07/01	BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating	MT
10/10/25	Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target	MT
03/04/25	RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk	MT
28/03/25	BofA Securities Upgrades Beam Therapeutics to Buy From Neutral	MT
11/03/25	Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target	MT
26/02/25	RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk	MT
29/01/25	Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral	MT
07/11/24	Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise	MT
07/11/24	RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating	MT
06/11/24	Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27	MT
16/10/24	Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target	MT
18/09/24	JonesTrading Initiates Beam Therapeutics at Hold	MT
24/07/24	Beam Therapeutics Shares Rise After HC Wainwright Starts Coverage at Buy	MT
23/07/24	HC Wainwright Initiates Beam Therapeutics at Buy With $80 Price Target	MT
09/07/24	RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk	MT
29/02/24	Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	MT
28/02/24	RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BEAM THERAPEUTICS INC.					+87.87%
	WUXI APPTEC CO., LTD.					+37.65%
	ARGENX SE					+23.19%
	LONZA GROUP AG					+7.56%
	BEONE MEDICINES AG					+12.87%
	IQVIA HOLDINGS INC.					+14.74%
	REVOLUTION MEDICINES, INC.					+42.01%
	CELLTRION, INC.					+29.95%
	GENMAB A/S					+15.03%
	INSMED INCORPORATED					+69.73%
	Average					+34.06%
	Weighted average by Cap.					+26.39%